Andson Biotech Inc.

Andson Biotech Inc. , headquartered in Atlanta, US, specializes in biotherapeutics solutions, focusing on enhancing mass spectrometry sample preparation for biopharmaceutical applications. Founded in 2021 by Andrei Fedorov and Mason Chilmonczyk, Andson Biotech Inc. operates from Atlanta, Georgia.

The company has completed 3 deals, with the latest funding round, a Seed round, raising USD 4. 7 mn, bringing the total amount raised to USD 4. 7 mn and a current valuation of USD 15. 27 mn.

Andson Biotech specializes in advanced biotherapeutics solutions, primarily focusing on simplifying mass spectrometry sample preparation. Their flagship products, including the DynaChip and DynaChip X1, are designed to enhance workflow efficiency in mass spectrometry, catering to researchers and laboratories involved in biopharmaceutical development. Andson Biotech generates revenue through direct sales of its proprietary sample preparation products and services, primarily engaging in B2B transactions with laboratories, research institutions, and pharmaceutical firms. Revenue is structured around individual product sales, with an emphasis on flagship offerings such as the DynaChip and DynaChip X1.

In October 2025, Andson Biotech Inc. raised USD 4. 7 mn in Seed funding, which will be used to transform the use of mass spectrometers in biotherapeutic development. The company aims to launch additional innovative products to enhance its portfolio and is targeting expansion into new markets across North America and Europe by 2026.